Viventia Biotechnologies Inc. (“Viventia”) is focused on building a pipeline of human antibodies directed against oncology drug targets. Viventia’s Armed Antibodies™ represent a differentiated approach to antibody development in oncology, addressing key limitations in the sector. In this approach, antibody fragments are employed to facilitate effective penetration of solid tumors, delivering a payload into the core of the tumor. Attached as stable recombinant fusions, Viventia’s payloads are designed to specifically activate within the cell and to remain inert outside the cell. Since conjugated antibody therapeutics comprise both the selectivity of tumor targeting with the potency of traditional anti-cancer therapies, these drugs hold significant promise as safe and effective standalone therapeutics.

Viventia has mAb products in various stages of preclinical and clinical development and continues to discover, screen and qualify numerous human mAbs each year for addition to its antibody portfolio.